Biotech entity
MarketBeat.com is most often covered alongside FiscalAI, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. They are less corroborated than the beat average, carrying 2 original sources each against 2.1 for the same window.
Last mentioned: 5d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
MarketBeat.com is most often covered alongside FiscalAI, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. They are less corroborated than the beat average, carrying 2 original sources each against 2.1 for the same window. Their average consequence score of 5 runs below the beat's 5.3 for that window. This profile follows 3 Biotech stories mentioning MarketBeat.com across the period from August 12, 2026 to August 17, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 33 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MarketBeat.com. Shared-story counts are live from our verified record — not editorial picks.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
Wall Street Zen rating action
Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).
Wall Street Zen downgrades MBRX
Cut its rating from 'sell' to 'strong sell' in a research note
Jane Street Group discloses new MBRX position
Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
A MarketBeat comparison finds NexGel beats Bluejay Diagnostics on 9 of 13 metrics, with a $2.00 target and 284.69% upside. The biotech lens highlights divergent risk profiles between a diagnostics platform and a biomaterials company.
Source: tickerreport.com · dailypolitical.com
MarketBeat.com is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
